Molecular insights into receptor binding energetics and neutralization of SARS-CoV-2 variants.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
30 11 2021
Historique:
received: 06 08 2021
accepted: 15 11 2021
entrez: 1 12 2021
pubmed: 2 12 2021
medline: 15 12 2021
Statut: epublish

Résumé

Despite an unprecedented global gain in knowledge since the emergence of SARS-CoV-2, almost all mechanistic knowledge related to the molecular and cellular details of viral replication, pathology and virulence has been generated using early prototypic isolates of SARS-CoV-2. Here, using atomic force microscopy and molecular dynamics, we investigated how these mutations quantitatively affected the kinetic, thermodynamic and structural properties of RBD-ACE2 complex formation. We observed for several variants of concern a significant increase in the RBD-ACE2 complex stability. While the N501Y and E484Q mutations are particularly important for the greater stability, the N501Y mutation is unlikely to significantly affect antibody neutralization. This work provides unprecedented atomistic detail on the binding of SARS-CoV-2 variants and provides insight into the impact of viral mutations on infection-induced immunity.

Identifiants

pubmed: 34848718
doi: 10.1038/s41467-021-27325-1
pii: 10.1038/s41467-021-27325-1
pmc: PMC8633007
doi:

Substances chimiques

Antibodies, Neutralizing 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6977

Subventions

Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
ID : 758224
Organisme : Fonds De La Recherche Scientifique - FNRS (Belgian National Fund for Scientific Research)
ID : CR-2019S-01

Informations de copyright

© 2021. The Author(s).

Références

Nat Nanotechnol. 2017 Feb;12(2):177-183
pubmed: 27798607
Intensive Care Med. 2021 Jul;47(7):786-789
pubmed: 34031699
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
J Chem Theory Comput. 2017 Mar 14;13(3):1366-1374
pubmed: 28195464
Cell Rep. 2021 Jan 12;34(2):108630
pubmed: 33417835
Science. 1978 May 12;200(4342):618-27
pubmed: 347575
ACS Nano. 2020 Aug 25;14(8):10616-10623
pubmed: 32806067
J Cell Physiol. 2021 Oct;236(10):7045-7057
pubmed: 33755190
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17778-83
pubmed: 18997008
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13626-31
pubmed: 22869709
Lancet Infect Dis. 2021 Aug;21(8):1070
pubmed: 34022142
Phys Biol. 2015 May 27;12(4):046002
pubmed: 26015431
Nat Methods. 2017 Jan;14(1):71-73
pubmed: 27819658
Ultramicroscopy. 2007 Oct;107(10-11):922-7
pubmed: 17560033
Anal Chem. 2019 Jun 4;91(11):7226-7235
pubmed: 31074606
Bioconjug Chem. 2011 Jun 15;22(6):1239-48
pubmed: 21542606
PLoS Biol. 2021 Apr 29;19(4):e3001237
pubmed: 33914735
Sci Adv. 2018 Aug 17;4(8):eaat1273
pubmed: 30128355
N Engl J Med. 2021 Jul 8;385(2):179-186
pubmed: 34161052
Elife. 2020 Jun 23;9:
pubmed: 32573433
Nat Rev Immunol. 2021 May;21(5):319-329
pubmed: 33824483
Nanoscale. 2020 Aug 21;12(31):16409-16413
pubmed: 32725017
Res Sq. 2021 Aug 11;:
pubmed: 34401873
Materials (Basel). 2020 Nov 26;13(23):
pubmed: 33255977
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Nat Rev Immunol. 2021 Jun;21(6):382-393
pubmed: 33875867
Cell. 2021 Apr 1;184(7):1671-1692
pubmed: 33743212
Science. 2021 Aug 6;373(6555):
pubmed: 34168071
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Nat Commun. 2020 Sep 11;11(1):4541
pubmed: 32917884
Microb Cell Fact. 2021 Apr 22;20(1):88
pubmed: 33888152
Sci Adv. 2021 Apr 16;7(16):
pubmed: 33863729
Nat Protoc. 2017 Nov;12(11):2275-2292
pubmed: 28981124
Proc Natl Acad Sci U S A. 2021 May 11;118(19):
pubmed: 33903171
Nat Commun. 2019 Oct 1;10(1):4460
pubmed: 31575869
Biophys J. 1995 Jun;68(6):2580-7
pubmed: 7647261
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Front Mol Biosci. 2021 Apr 22;8:671633
pubmed: 33968996

Auteurs

Melanie Koehler (M)

Louvain Institute of Biomolecular Science and Technology, Université catholique de Louvain, Louvain-la-Neuve, Belgium.

Ankita Ray (A)

Louvain Institute of Biomolecular Science and Technology, Université catholique de Louvain, Louvain-la-Neuve, Belgium.

Rodrigo A Moreira (RA)

Institute of Fundamental Technological Research, Polish Academy of Sciences, Pawińskiego 5B, 02-106, Warsaw, Poland.

Blinera Juniku (B)

Louvain Institute of Biomolecular Science and Technology, Université catholique de Louvain, Louvain-la-Neuve, Belgium.

Adolfo B Poma (AB)

International Center for Research on Innovative Biobased Materials (ICRI-BioM)-International Research Agenda, Lodz University of Technology, Żeromskiego 116, 90-924, Lodz, Poland. adolfo.poma-bernaola@p.lodz.pl.

David Alsteens (D)

Louvain Institute of Biomolecular Science and Technology, Université catholique de Louvain, Louvain-la-Neuve, Belgium. david.alsteens@uclouvain.be.
Walloon Excellence in Life sciences and Biotechnology (WELBIO), 1300, Wavre, Belgium. david.alsteens@uclouvain.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH